

# BLOOD CYTOKINE EVALUATION IN PATIENTS WITH INTRAVITREAL RANIBIZUMAB FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION

Laura García-Quintanilla\*<sup>1</sup>, Pablo Almuiña-Varela<sup>2</sup>, Cristina Mondelo-García<sup>1</sup>, María Gil-Martínez<sup>2</sup>, Maximino J. Abraldes, María José Rodríguez-Cid<sup>2</sup>, María Isabel Fernández-Rodríguez<sup>2</sup>, Ana Castro-Balado<sup>1</sup>, Irene Zarra-Ferro<sup>1</sup>, Anxo Fernández-Ferreiro<sup>1</sup>

<sup>1</sup> PHARMACY DEPARTMENT. UNIVERSITY CLINICAL HOSPITAL SANTIAGO DE COMPOSTELA (CHUS) (SERGAS)

<sup>2</sup> OPHTHALMOLOGY DEPARTMENT. UNIVERSITY CLINICAL HOSPITAL SANTIAGO DE COMPOSTELA (CHUS) (SERGAS)

\*laura.garcia.quintanilla@sergas.es

6ER-027

## BACKGROUND AND IMPORTANCE


Inflammation is involved in the development and pathogenesis of Age-related Macular Degeneration (n-AMD) although the roles that the inflammation-related cytokines play in it are not yet defined as some of them are pro-angiogenic. Local and systemic inflammatory molecules are being proposed as potential biomarkers of n-AMD progression.

## AIM AND OBJECTIVE

The aim of this study is to evaluate cytokine values after the ranibizumab loading phase in patients with n-AMD.

## MATERIAL AND METHODS

Prospective, observational study of n-AMD patients with criteria to initiate treatment with ranibizumab



## RESULTS




### DEMOGRAPHICS

- 45 patients included
  - 60% women
  - Mean age: 80±8 years

- ✓ 41 patients responded to treatment (14 partially)
- ✓ 2 did not respond to treatment
- ✓ 2 did not finished loading phase

### Responders



IL-5 and IL-10 remained undetected over time in both responders and non-responder patients

## CONCLUSION

- Changes at the end of loading phase in IL-6 and IL-8 have been described previously with the administration of antiangiogenics but no statistical differences were detected in our study, probably due to the low sample size.
- More studies will be necessary to determine the prognostic potential of the change in systemic cytokines as a response parameter in patients treated with antiangiogenics in n-AMD.

## ACKNOWLEDGEMENTS

This study was partially supported by Health Institute Carlos III and co-financed by European Union (ISCIII\_PI17/00940\_FEDER, RETICS Oftared, RD16/0008/0003 y RD12/0034/0017)